{"entity":{"id":"nct07131514","kind":"trial","name":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","aka":[],"tldr":"A phase 2 trial of adebrelimab in pancreatic cancer, run by Ruijin Hospital, now recruiting.","summary":"HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer is a phase 2, interventional study registered as NCT07131514 by Ruijin Hospital, with a registry enrolment figure of 30 participants, started 2025-08-25 and due to reach its primary completion in 2027-06. Interventions recorded: HRS-4642+AG +Adebrelimab. Conditions listed: Pancreatic Cancer. Primary outcome: Adverse events (AEs); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: \"Pathologically or cytologically confirmed ductal adenocarcinoma of the pancreas; and subjects must have at least one measurable lesion as defined by RECIST v1\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07131514","url":"https://clinicaltrials.gov/study/NCT07131514"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["resectable-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07131514","phase":"2","setting":"An Exploratory Clinical Study of HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer","sponsor":"Ruijin Hospital","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07131514/","neighbours":{"cancer":[{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}